A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

NCT06817356 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing whether the experimental drug mazudutide is safe and effective for adults with alcohol use disorder compared to a placebo.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind study

Participants 300 people Planned (estimated).

Who can join Ages 21–65 · all sexes

Timeline Started 2025-02 · est. completion 2026-08

Where 25 sites · United States

What this study is testing ClinicalTrials.gov NCT06817356 ↗

Description as written by the study sponsor.

The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.

Treatments tested

Mazdutide also known as LY3305677 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Behaviors Associated with Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method
Sponsor	Eli Lilly and Company
Conditions studied	Alcohol Use Disorder
GLP-1 drugs	mazdutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06817356 ↗